This article is more than 5 years old. Information may no longer be current.

Valeant, Actavis reach agreement on Acanya Gel for acne

Subsidiaries of Valeant Pharmaceuticals have reached settlement agreements with Actavis affiliates related to Actavis’ generic version of clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5%, according to a press release.

Valeant’s Dow Pharmaceuticals Sciences and Valeant Pharmaceuticals North America have entered into an agreement with Actavis’ Watson Laboratories to settle all outstanding patent litigation related to Acanya Gel 1.2%/2.5%, a lincosamide antibiotic and benzoyl peroxide indicated for topical treatment of acne vulgaris, according to the release. Actavis will be given a license by Valeant to market generic Acanya Gel on July 1, 2018, or earlier, depending on circumstances that the release did not disclose.

The product’s launch is contingent upon final approval from the FDA on Actavis’ abbreviated new drug application for generic Acanya Gel, according to the release.